Order results by:
| Issue | Title | |
| Vol 7, No 3 (2014) | ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva | ||
| "... orphan diseases were 15.73 bln rubles per year (6.36 bln rubles for children and 9.37 bln rubles ..." | ||
| Vol 14, No 4 (2021) | Economic outcomes of centralized procurements of gene therapy for patients with orphan diseases: inherited retinal dystrophy | Abstract similar documents |
| N. А. Avxentyev, Yu. V. Makarova, V. V. Kadyshev | ||
| "... procurements. Conclusion. Centralizing procurements of expensive drugs intended for gene therapy of orphan ..." | ||
| Vol 18, No 2 (2025) | Population consumption of antihypertensive and lipid-lowering drugs in the Russian Federation (SPARDEC) | Abstract similar documents |
| Zh. D. Kobalava, I. K. Petrukhina, P. A. Lebedev, P. R. Blinkova, T. K. Ryazanova, E. P. Gladunova, E. V. Paranina | ||
| "... the need for long-term pharmacotherapy with antihypertensive and lipid-lowering drugs. Objective: To study ..." | ||
| Vol 12, No 4 (2019) | Optimization of drug supply for patients with malignant neoplasms in a region of the Russian Federation | Abstract similar documents |
| A. V. Nikitina, F. V. Gorkavenko, Y. S. Saybel, M. V. Avxentyeva, M. S. Sura, D. V. Fedyaev | ||
| "... the costs of drugs for solid tumors at the 352.2 million rubles for 5 years (baseline scenario), 69 ..." | ||
| Vol 14, No 4 (2021) | Features of intellectual property protection mechanisms on the example of orphan drugs circulation | Abstract similar documents |
| D. S. Yurochkin, К. V. Nasonova, Z. М. Golant, I. А. Narkevich, V. P. Trukhin | ||
| "... of drugs for the treatment of rare (orphan) diseases. Material and methods. Analysis of pharmaceutical ..." | ||
| Vol 9, No 2 (2016) | METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY | Abstract similar documents |
| N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov | ||
| "... Targeted drugs are recommended for treatment of metastatic colorectal cancer. Second and further ..." | ||
| Vol 8, No 2 (2015) | REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS | Abstract similar documents |
| Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev | ||
| "... Orphan drugs are used for treatment of rare life-threatening diseases. There is no universal ..." | ||
| Vol 9, No 2 (2016) | PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA | Abstract similar documents |
| N. A. Avxentyev, M. Yu. Frolov | ||
| "... combined drug is cost saving alternative that annually requires 22,000 rubles per patient, which is 2 ..." | ||
| Vol 7, No 4 (2014) | APPLICATION OF MULTIPLE-CRITERIA ANALYSIS FOR OPTIMIZATION OF FINANCING OF RARE DISEASES | Abstract similar documents |
| V. V. Omelyanovskiy, V. K. Fedyaeva, O. Yu. Rebrova | ||
| "... financing of rare disease drugs remains a serious problem for both foreign countries and our ..." | ||
| Vol 17, No 3 (2024) | Economic analysis of implementing Systemic Coronary Risk Estimation (SCORE2) scale and long-term consequences | Abstract similar documents |
| E. O. Kurilovich, A. V. Nikitina, I. V. Sorokovikov | ||
| "... associated with CV events at outpatient and inpatient stages of medical care. The costs of drug therapy were ..." | ||
| Vol 18, No 1 (2025) | The sale of medicines used for diabetes mellitus treatment in retail segment of Russian pharmaceutical market | Abstract similar documents |
| I. K. Petrukhina, A. M. Lazarev, T. K. Ryazanova, P. A. Lebedev, E. P. Gladunova, G. T. Glembotskaya | ||
| "... , 54.9 million packages of antidiabetic drugs were sold for 32.4 billion rubles from 2020 to 2023 ..." | ||
| Vol 12, No 3 (2019) | Pharmacoepidemiological analysis of antimicrobial therapy for burn injury in the hospital settings | Abstract similar documents |
| O. V. Zhukova, E. S. Nekaeva, E. S. Khoroshavina, E. A. Kozlova, Yu. A. Dudukina, I. Yu. Arefyev | ||
| "... ) analysis was used to evaluate the actual drug consumption based on the defined daily dose; DU90% (Drug ..." | ||
| Vol 14, No 2 (2021) | Organizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting | Abstract similar documents |
| E. A. Pyadushkina, E. V. Derkach, V. I. Ignatyeva, E. E. Yagnenkova, T. Yu. Klitochenko, T. V. Shelekhova, A. N. Levanov | ||
| "... patient in the case of centralized procurement of drugs ranged from 5.51 million rubles (regimen ..." | ||
| Vol 13, No 4 (2020) | Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia | Abstract similar documents |
| V. G. Deriushkin, A. P. Ternavskii, S. V. Gatsura | ||
| "... The study aimed to perform a pharmacoeconomic analysis of antimicrobial drugs (AMDs) prescribed ..." | ||
| Vol 14, No 3 (2021) | Pharmacoeconomic features of drug provision to the rheumatology department of the republican clinical hospital | Abstract similar documents |
| L. N. Sheikhmambetova, E. A. Egorova, K. N. Onishchenko, E. I. Konyaeva | ||
| "... of drugs for rheumatology department was 5,308,775.23 rubles. The list of medicines for the department ..." | ||
| Vol 14, No 3 (2021) | Health economic evaluation of risdiplam in patients with spinal muscular atrophy | Abstract similar documents |
| А. S. Kolbin, А. А. Kurylev, Yu. Е. Balykina, М. А. Proskurin, S. А. Mishinova | ||
| "... orphan diseases leading to progressive spinal motoneurons degeneration and loss of function. Risdiplam ..." | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia | Abstract similar documents |
| N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov | ||
| "... are registered in second-line, however only dasatinib is included in the government drug reimbursement program ..." | ||
| Vol 10, No 1 (2017) | EVALUATION OF DRUG THERAPY IN PROGRESSING DIFFERENTIATED THYROID CANCER REFRACTORY TO RADIOACTIVE IODINE IN PATIENTS RESIDING IN THE RUSSIAN FEDERATION : PHARMACOECONOMIC ASPECTS | Abstract similar documents |
| M. Yu. Frolov, V. A. Rogov | ||
| "... aspects) drug for the treatment of widespread progressing differentiated thyroid cancer (DTC) refractory ..." | ||
| Vol 9, No 3 (2016) | CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY | Abstract similar documents |
| E. A. Pyadushkina, M. Yu. Frolov | ||
| "... of the Russian Federation in three scenarios: Lacosamide as concomitant drug to standard therapy in comparison ..." | ||
| Vol 14, No 1 (2021) | Analysis of acquisition and the monthly cost of antihypertensive therapy with modern fixed-dose combinations in the Far Eastern Federal District | Abstract similar documents |
| M. S. Soboleva, E. E. Loskutova | ||
| "... – 500–1000 rubles. The most popular three-component drugs were valsartan+amlodipine+hydrochlorothiazide ..." | ||
| Vol 16, No 2 (2023) | Pharmacoeconomic analysis of antiretroviral therapy regimes in the Syrian Arab Republic | Abstract similar documents |
| Yu. Sh. Gushchina, А. Yu. Abramov, Y. J. Haitham | ||
| "... for Russian drugs Timazid® (zidovudine) – 471.0 rubles and Nikavir® (phosphazide) – 743.8 rubles (both – AZT ..." | ||
| Vol 16, No 4 (2023) | Sales of antitumor drugs in the retail segment of the Russian pharmaceutical market | Abstract similar documents |
| I. K. Petrukhina, T. K. Ryazanova, E. P. Gladunova, A. M. Lazarev, A. A. Krivova | ||
| "... Objective: to study the features of the population consumption of antitumor drugs (ATDs) of groups ..." | ||
| Vol 11, No 3 (2018) | Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus | Abstract similar documents |
| A. G. Tolkushin, N. L. Pogudina | ||
| "... from analysis of published clinical and observational studies. The prices of the relevant drugs were ..." | ||
| Vol 17, No 1 (2024) | Pharmacoeconomic evaluation of first-line combination therapy with immunotherapy drugs and platinum-containing chemotherapy in adult patients with metastatic non-squamous non-small cell lung cancer | Abstract similar documents |
| S. К. Zyryanov, I. N. Dyakov | ||
| "... + carboplatin” drug combination compared to “pembrolizumab + pemetrexed + carboplatin” combination in adult ..." | ||
| Vol 17, No 2 (2024) | Cost-effectiveness analysis of acalabrutinib in treatment of patients with relapsed/refractory form of mantle cell lymphoma who previously received at least one line of therapy | Abstract similar documents |
| S. K. Zyryanov, I. N. Dyakov | ||
| "... was developed. The model was used to calculate drug costs over a 3-year horizon. To explore uncertainty ..." | ||
| Vol 17, No 2 (2024) | Clinical and economic assessment of using IRS®19 for the treatment and prevention of acute respiratory infections in children | Abstract similar documents |
| A. S. Kolbin, A. R. Kasimova | ||
| "... infections in pediatric population in comparison with other drugs registered in Russia, belonging ..." | ||
| Vol 16, No 3 (2023) | Comparative analysis of using atezolizumab vs. durvalumab in combination with platinum-containing chemotherapy in adult patients with advanced small cell lung cancer | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova | ||
| "... with advanced small cell lung cancer (SCLC), but with the advent of new immunological drugs, immune checkpoint ..." | ||
| Vol 16, No 1 (2023) | Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program | Abstract similar documents |
| T. O. Bessonova, P. A. Mukhortova, R. A. Teryan, A. D. Bagdasarov, N. Z. Musina | ||
| "... Objective: to evaluate the clinical and economic feasibility of expanding the preferential drug ..." | ||
| Vol 18, No 1 (2025) | Pharmacoeconomic analysis of lanreotide and prolonged-release octreotide in first- and second-line therapy of acromegaly | Abstract similar documents |
| I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova, D. V. Kurkin | ||
| "... was developed, accounting for direct medical costs for drugs and surgical intervention. A pharmacoeconomic study ..." | ||
| Vol 16, No 2 (2023) | Comparative pharmacoeconomic analysis of follitropin delta application for superovulation induction during artificial insemination | Abstract similar documents |
| I. S. Krysanov, V. S. Krysanova, V. Yu. Ermakova | ||
| "... )), the cost-effectiveness analysis was used. The cost analysis included only direct medical costs: drugs ..." | ||
| Vol 10, No 1 (2017) | RESTRICTIVE LISTS OF DRUGS: REGULATIONS, FUNCTIONS, SOURCES OF FINANCE, AND GUIDELINES FOR CREATION | Abstract similar documents |
| M. V. Sura | ||
| "... and sources of finance pertaining to the restrictive lists of drugs, which play a substantial role in the drug ..." | ||
| Vol 16, No 1 (2023) | Updated clinical and economic analysis of using follitropin alfa in combination with assisted reproductive technologies in 2022 | Abstract similar documents |
| D. G. Shchurov, D. V. Blinov, N. V. Bashmakova, M. A. Polzikov, A. S. Semikhin | ||
| "... Objective: to perform a clinical and economic analysis of using drugs containing follitropin alfa ..." | ||
| Vol 16, No 2 (2023) | Сlinical and economic evaluation of various etiotropic chemotherapy regimens in patients with respiratory tuberculosis with multidrug and extensively drug resistance | Abstract similar documents |
| N. Yu. Nikolenko, D. A. Kudlay, S. E. Borisov, T. E. Sannikova, N. P. Doktorova | ||
| "... in patients with respiratory tuberculosis with multidrug- and extensively drug-resistant (MDR and XDR ..." | ||
| Vol 14, No 2 (2021) | Medical care payment improvement within diagnosis-related groups of patients with severe asthma requiring biologic disease-modifying drugs by regional adaptation mechanism in the Moscow Region | Abstract similar documents |
| A. D. Ermolaeva, V. S. Krysanova, T. N. Ermolaeva, K. I. Polyakova, K. A. Kokushkin | ||
| "... drugs (bDMDs) within the constraints of diagnosis-related groups (DRGs) on the level of the Moscow ..." | ||
| Vol 12, No 2 (2019) | Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria | Abstract similar documents |
| S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova | ||
| "... the reference drug combinations (8 vs 18 days and 75% vs 34.8%, respectively, p=0.031). The cost of treatment ..." | ||
| Vol 15, No 2 (2022) | Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings | Abstract similar documents |
| M. V. Zhuravleva, S. N. Avdeev, Yu. V. Gagarina, T. V. Marin | ||
| "... costs included drug cost and outpatient patient monitoring services cost. Results. The direct medical ..." | ||
| Vol 16, No 3 (2023) | Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable BRAF V600-mutated metastatic melanoma in Russia | Abstract similar documents |
| N. A. Avxentyev, Yu. V. Makarova | ||
| "... and vemurafenib monotherapy, which are listed in the Russian clinical guidelines and the Vital and Essential Drugs ..." | ||
| Vol 17, No 2 (2024) | Clinical and economic assessment of using topical bacterial lysate Imudon® for the treatment and prevention of acute upper respiratory tract infections in children | Abstract similar documents |
| A. R. Kasimova, A. S. Kolbin | ||
| "... to be prescribed antibacterial drugs), and unfavorable (when confirmed bacterial infection joins and antibiotics ..." | ||
| Vol 15, No 1 (2022) | Pharmacoeconomic analysis of using Monofer in patients with iron deficiency anemia as part of the provision of medical care under the state guarantees program in the health care system of the Russian Federation | Abstract similar documents |
| R. I. Yagudina, A. Yu. Kulikov, V. G. Serpik, O. A. Gromova, I. Yu. Torshin | ||
| "... of an increase in hemoglobin blood levels over time in treatment with the drugs under consideration ..." | ||
| Vol 16, No 3 (2023) | Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study | Abstract similar documents |
| A. S. Kolbin, Yu. M. Gomon, M. A. Proskurin, Yu. E. Balykina | ||
| "... system: the costs of drug therapy, detecting and relieving adverse events, palliative care. A Markov ..." | ||
| Vol 9, No 3 (2016) | METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL | Abstract similar documents |
| O. V. Zhukova, S. V. Kononova | ||
| "... obstructive bronchitis in children. The original drug Augmentin (Smithkline Beecham Pharmaceuticals ..." | ||
| Vol 8, No 4 (2015) | ABC-, VEN- AND FREQUENCY ANALYSIS OF TREATMENT OF ATRIAL FIBRILLATION IN OUTCOME PATIENTS | Abstract similar documents |
| A. N. Korobeynikova, S. V. Malchikova | ||
| "... studies allow to evaluate the quality of drug therapy for atrial fibrillation, find rational drug usage ..." | ||
| Vol 18, No 1 (2025) | Reorganization of public procurement of biosimilars and its economic effect on the monoclonal antibody market in Russia | Abstract similar documents |
| A. Yu. Efremov, A. M. Vlasov, V. I. Gegechkori, N. V. Gorpinchenko, G. V. Ramenskaya, T. M. Litvinova | ||
| "... of rituximab drugs, procurement of biosimilars led to savings of approximately 2 billion rubles. Conclusion ..." | ||
| Vol 18, No 2 (2025) | Data analysis of medicines aimed at health technology assessment within the activities of the “Circle of Kindness” Foundation from 2021 to 2024 | Abstract similar documents |
| V. V. Omelyanovskiy, A. A. Kingshott, T. S. Teptsova, P. A. Mukhortova, A. G. Kharitonova, S. I. Zinadinov, L. O. Krekhtunova, N. A. Aldushchenko, A. А. Kozak, V. A. Ryagina | ||
| "... and orphan ones) requiring essential treatment, particularly expensive medicines. At the same time ..." | ||
| Vol 10, No 2 (2017) | CLINICAL AND ECONOMIC EVALUATION OF CHRONIC DISEASE TREATMENT: A DISCREPANCY BETWEEN THE TRADITIONAL PHARMACOECONOMIC AND SOCIO-ECONOMIC ANALYSES | Abstract similar documents |
| O. V. Zhukova, S. V. Kononova | ||
| "... in medical costs from 873.00 rubles to 1515.39 rubles, and to a decrease in the average number ..." | ||
| Vol 14, No 2 (2021) | Pharmacoeconomic aspects of oral vinorelbine application: a budget impact analysis considering the new registered price | Abstract similar documents |
| D. A. Ivanov, I. N. Dyakov, S. K. Zyryanov | ||
| "... of the dosage, frequency and dosage regimen of the compared drugs, based on the data of the State Register ..." | ||
| Vol 10, No 2 (2017) | COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov | ||
| "... medication reached 4,888 rubles, which is 13% less than that with the mono-component drug. If the current ..." | ||
| Vol 5, No 3 (2012) | PHARMACOECONOMIC EVALUATION OF TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS ON DIALYSIS WITH CINACALCET | Abstract similar documents |
| R. I. Yagudina, V. G. Serpik | ||
| "... Abstract: the pharmacoeconomic study compared the standard drug therapy (vitamin D ..." | ||
| Vol 6, No 3 (2013) | PHARMACOECONOMIC ANALYSIS OF NEUROPROTECTIVE DRUGS IN THE TREATMENT OF ACUTE DISORDERS OF CEREBRAL CIRCULATION | Abstract similar documents |
| A. Yu. Kulikov, I. Yu. Zinchuk | ||
| "... Based on meta-analysis dates found, that the effectiveness of neuroprotective drugs and placebo ..." | ||
| Vol 13, No 4 (2020) | The social-economic burden of spinal muscular atrophy in Russia | Abstract similar documents |
| A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko, N. Yu. Kolbina | ||
| "... congenital orphan diseases that lead to progressive spinal motoneurons degeneration and loss ..." | ||
| 1 - 50 of 286 Items | 1 2 3 4 5 6 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
